




Efficacy of MPLA Preconditioning for Severe Radiation-Combined Burn Injury: Improving Survival and Reducing Vascular Leakage

Lt Colonel Kohei Yamada¹, MD, MPH, Masafumi Saito¹, PhD, Major Bradley M. Kearney^{1,2}, PhD, Major Kazuma Mori¹, MD, LCDR Ryohei Suematsu¹, MD, Azusa Kato¹, MD, PhD, Masahiro Nakashima¹, MD, PhD, Hiroyuki Nakashima¹, MD, PhD and Manabu Kinoshita¹, MD, PhD

1) Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan, 2) U.S. Army Japan ESEP, Camp Zama, Tokyo, Japan



BACKGROUND

Radiation-Combined Burn injury (RCB)

- Escalating global instability makes nuclear weapon use or attacks on nuclear power plants a realistic threat.
- In radiological events, up to 70 % of victims may have whole-body irradiation (WBI) plus physical trauma.
- Among these patients, thermal burns are the most common associated trauma, producing **Radiation-Combined Burn injury (RCB)**.
- RCB patients often deteriorate catastrophically during the acute phase because of complex, poorly understood **synergistic effects**.
- Study objective:** Identify new Medical Countermeasures (MCMs) that can rescue severely injured RCB patients during the acute phase.

MPLA preconditioning

- MPLA** is a detoxified derivative of the lipid A component of **LPS** that retains TLR4 agonist activity and activates innate immune responses.
- Low-dose endotoxin preconditioning has various known effects on the immune system.
 - **Enhances phagocytic activity**
 - **Limits excessive inflammatory responses**




Figure 1. Schematic structure of lipopolysaccharide (LPS), highlighting the lipid A portion

This makes **MPLA preconditioning** an attractive medical countermeasure candidate for RCB.

METHODS

Mouse Model: C57BL/6J, male, 8–12 weeks old, 20–25 g
Whole Body Irradiation (WBI): 6 Gy of X-ray (0.4 Gy/min)
Burn injury (20% TBSA Burn): 20% Total Body Surface Area full-thickness burn + N.S. 500 μ L *i.p.*
Radiation-Combined Burn (RCB): 6 Gy WBI $\rightarrow$ 20% Burn, + N.S. 500 μ L *i.p.*

MPLA injected *i.p.* once per day for two days.

- MPLA+ (preconditioning):** MPLA 10 μ g + 500 μ L N.S.
- MPLA- (vehicle):** 500 μ L N.S.




Figure 2. Experimental timeline and injury protocol

- **Survival**
- **Vascular permeability**
- **Intestinal permeability**
- **Cytokine & Chemokine**
- etc.

RESULTS




Figure 3. Thirty-day survival across injury groups (Kaplan-Meier curves)

- WBI alone (6 Gy) and Burn alone (20 % TBSA): **100% survival**
- RCB + vehicle (purple line): 30-day survival fell to **10%**, most deaths occurring within the **first 24–48 h**.
- RCB + MPLA preconditioning (orange line): boosted 30-day survival to **80%**.
- The benefit is concentrated in the **acute phase**, preventing the early deaths from RCB. (n=10), *** $p < 0.001$ (log-rank)





Figure 4. Findings related to hemoconcentration and vascular leakage at 6 h post-injury

- (A) RCB caused marked **hemoconcentration**, which was attenuated by MPLA preconditioning.
 - (B) MPLA preconditioning preserved **serum albumin** (HCT-adjusted) after RCB.
 - (C) MPLA preconditioning increased intravascular FITC-**albumin retention** after RCB.
 - (D–F) Mesenteric Evans blue extravasation was observed using a stereomicroscope; **leakage** was increased after RCB and reduced by MPLA preconditioning.
- Together, these findings indicate that **MPLA preconditioning attenuates early vascular leakage after RCB**. (n = 6–10, mean $\pm$ SD), * $p < 0.05$, *** $p < 0.001$

RESULTS (continued)



CONCLUSIONS

- Severe RCB caused rapid **vascular leakage** and **early mortality**.
- MPLA preconditioning **dramatically improved survival** and attenuated early vascular leakage.
- KC contributed to **RCB-associated vascular leakage** and was reduced by MPLA.
- MPLA may serve as a **pre-exposure MCM** for personnel operating under a credible radiological threat.

Additional findings:

MPLA also attenuated intestinal hyperpermeability and bacterial translocation after RCB.

Engelhardt et al. Der Unfallchirurg 2001
Palmer et al. J of Burn care and research 2011
Kinoshita et al. J of Innate immunity 2017
Ono et al. Infect Immun. 2021
Koga et al. Progress in Neuro-psych. and biological psychi. 2020
Nishikawa et al. J Gastroenterol Hepatol. 2021

Disclaimer: The opinions and assertions expressed herein are those of the authors and do not reflect the official policy or position of the Japan Self-Defense Forces, the U.S. Army, the U.S. Department of Defense or the Japan Ministry of Defense.
Email: drkhymd@ndmc.ac.jp (LTC Kohei Yamada, MD, MPH)